DK2760860T3 - Nitrogensennep-derivater - Google Patents
Nitrogensennep-derivater Download PDFInfo
- Publication number
- DK2760860T3 DK2760860T3 DK12836986.5T DK12836986T DK2760860T3 DK 2760860 T3 DK2760860 T3 DK 2760860T3 DK 12836986 T DK12836986 T DK 12836986T DK 2760860 T3 DK2760860 T3 DK 2760860T3
- Authority
- DK
- Denmark
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- alkyl
- compound according
- refers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (13)
- NITROGENSENNEP-DERIVATER1. Forbindelse med formlen (\ 1 eller farmaceutisk accentabelt salt deraf:Formel (1) hvor hver af Xi og X2 uafhængigt er halo eller OS02Ra, hvori Ra er alkyl, alkenyl eller alkynyl; Q er cycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, eller heteroaryl, hvoraf hver eventuelt er substitueret med alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclo alkyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, halo, nitro, oxo, -CF1=NH, cyano, alkyl-Rb, CFl=NORb, ORb, 0C(0)Rb, 0C(0)0Rb, 0C(0)SRb, SRb, C(0)Rb, C(0)ORb, C(0)SRb, C(0)NRcRd, SORb, S02Rb, NRcRd, alkyl-NRcRd eller N(Rc)C(0)Rd, hvori hver af Rb, Rc, og Rd uafhængigt er H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, cyano, nitro, amino, hydroxyl, alkylamino, haloalkyl eller alkoxy; Z er slettet eller (CH2)m, hvori m er et heltal fra 1 til 10; og hver af R, og R2 uafhængigt er H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, halo, nitro, oxo, -CH=NF1, cyano, alkyl-Rb, CFl=NORb, ORb, 0C(0)Rb, OC(0)ORb, 0C(0)SRb, SRb, C(0)Rb, C(0)0Rb, C(0)SRb, C(0)NRcRd, SORb, S02Rb, NRcRd, alkyl-NRcRd eller N(Rc)C(0)Rd, hvor: cycloalkyl refererer til et mættet carbonhydridsringsystem med 3 til 30 carbonatomer; cycloalkenyl refererer til et non-aromatisk carbonhydridringsystem med 3 til 30 carbonatomer og én eller flere dobbeltbindinger; heterocycloalkyl refererer til et non-aromatisk 5-8-leddet monocyklisk, 8-12-leddet bicyklisk eller 11-14-leddet tricyklisk ringsystem med ét eller flere heteroatomer; heterocycloalkenyl refererer til et non-aromatisk 5-8-leddet monocyklisk, 8-12-leddet bicyklisk, eller 11-14-leddet tricyklisk ringsystem med ét eller flere heteroatomer og én eller flere dobbeltbindinger; aryl refererer til et 6-carbon- monocyklisk, 10-carbon- bicyklisk, 14-carbon- tricyklisk aromatisk ringsystem; heteroaryl refererer til et aromatisk 5-8-leddet monocyklisk, 8-12-leddet bicyklisk eller 11-14-leddet tricyklisk ringsystem med ét eller flere heteroatomer; alkyl refererer til et lige eller forgrenet carbonhydrid, der indeholder 1-20 carbonatomer; alkenyl refererer til et lige eller forgrenet carbonhydrid, der indeholder 2-20 carbonatomer og én eller flere dobbeltbindinger; og alkynyl refererer til et lige eller forgrenet carbonhydrid, der indeholder 2-20 carbonatomer og én eller flere tripelbindinger.
- 2. Forbindelse ifølge krav 1 eller farmaceutisk acceptabelt salt deraf, hvor Ri er H, alkyl, alkenyl, eller alkynyl og R2 er H.
- 3. Forbindelse ifølge krav 2, der er repræsenteret ved formlen (2) eller farmaceutisk acceptabelt salt deraf:(Formel 2)
- 4. Forbindelse ifølge krav 3 eller farmaceutisk acceptabelt salt deraf, hvor Q er et aryl eller heteroaryl.
- 5. Forbindelse ifølge krav 4 eller farmaceutisk acceptabelt salt deraf, hvor Q er et 5-6-leddet aryl eller heteroaryl.(Formel 3)
- 6. Forbindelse ifølge krav 5, der er repræsenteret ved formlen (3) eller farmaceutisk acceptabelt salt deraf hvor R3 er H eller nitro; n er 0, 1,2 eller 3.
- 7. Forbindelse ifølge krav 4 eller farmaceutisk acceptabelt salt deraf, hvor Q er et 9-1 O-leddet aryl eller heteroaryl.(Formel 4)
- 8. Forbindelse ifølge krav 7, der er repræsenteret ved formlen (4) eller farmaceutisk acceptabelt salt deraf:
- 9. Forbindelse ifølge krav 1 eller farmaceutisk acceptabelt salt deraf, hvor forbindelsen er
- 10. Forbindelse ifølge krav 1 eller farmaceutisk acceptabelt salt deraf, hvor forbindelsen er
- 11. Forbindelse ifølge krav 1 eller farmaceutisk acceptabelt salt deraf, hvor forbindelsen er
- 12. Farmaceutisk sammensætning, der omfatter en forbindelse ifølge krav 1 eller farmaceutisk acceptabelt salt deraf og en farmaceutisk acceptabel bærer.
- 13. Forbindelse ifølge krav 1 eller farmaceutisk acceptabelt salt deraf til anvendelse i en fremgangsmåde til behandling af en neoplastisk sygdom eller en immunsygdom, hvilken fremgangsmåde omfatter administration til en person med behov derfor af en effektiv mængde af forbindelsen eller det farmaceutisk acceptable salt deraf.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161540523P | 2011-09-28 | 2011-09-28 | |
PCT/US2012/057445 WO2013049279A2 (en) | 2011-09-28 | 2012-09-27 | Nitrogen mustard derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2760860T3 true DK2760860T3 (da) | 2017-02-27 |
Family
ID=47996730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12836986.5T DK2760860T3 (da) | 2011-09-28 | 2012-09-27 | Nitrogensennep-derivater |
Country Status (21)
Country | Link |
---|---|
US (1) | US8962855B2 (da) |
EP (1) | EP2760860B8 (da) |
JP (1) | JP6008972B2 (da) |
AR (1) | AR088075A1 (da) |
AU (1) | AU2012316084B2 (da) |
CA (1) | CA2850541C (da) |
CY (1) | CY1118626T1 (da) |
DK (1) | DK2760860T3 (da) |
ES (1) | ES2616242T3 (da) |
HR (1) | HRP20170196T1 (da) |
HU (1) | HUE031445T2 (da) |
IL (1) | IL231170A (da) |
LT (1) | LT2760860T (da) |
MX (1) | MX342746B (da) |
PL (1) | PL2760860T3 (da) |
PT (1) | PT2760860T (da) |
RS (1) | RS55680B1 (da) |
SI (1) | SI2760860T1 (da) |
SM (1) | SMT201700108B (da) |
TW (1) | TW201326162A (da) |
WO (1) | WO2013049279A2 (da) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010343102B2 (en) | 2009-12-29 | 2016-03-24 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
US9944670B2 (en) * | 2013-12-04 | 2018-04-17 | Hangzhou Yuanchang Medical Sci-Tech Co., Ltd | Gemcitabine derivatives, compositions comprising same and pharmaceutical applications thereof |
KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
GB201409471D0 (en) * | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
CA2996978A1 (en) * | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
CA3040155C (en) | 2016-10-11 | 2024-01-16 | Euro-Celtique S.A. | Compound for use in the treatment of hodgkin lymphoma |
GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5882941A (en) * | 1994-05-04 | 1999-03-16 | Massachusette Institute Of Technology | Programmable genotoxic agents and uses therefor |
US6214852B1 (en) * | 1998-10-21 | 2001-04-10 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
US6392053B2 (en) | 1999-12-15 | 2002-05-21 | Bristol-Myers Squibb Company | Process for preparing arylacetylaminothiazoles |
US20080221132A1 (en) * | 2006-09-11 | 2008-09-11 | Xiong Cai | Multi-Functional Small Molecules as Anti-Proliferative Agents |
TW200922564A (en) * | 2007-09-10 | 2009-06-01 | Curis Inc | CDK inhibitors containing a zinc binding moiety |
US8309554B2 (en) * | 2008-05-15 | 2012-11-13 | Threshold Pharmaceuticals | Hypoxia activated drugs of nitrogen mustard alkylators |
WO2010075542A1 (en) | 2008-12-23 | 2010-07-01 | Curis, Inc. | Cdk inhibitors |
-
2012
- 2012-09-27 DK DK12836986.5T patent/DK2760860T3/da active
- 2012-09-27 AU AU2012316084A patent/AU2012316084B2/en active Active
- 2012-09-27 AR ARP120103588A patent/AR088075A1/es not_active Application Discontinuation
- 2012-09-27 ES ES12836986.5T patent/ES2616242T3/es active Active
- 2012-09-27 LT LTEP12836986.5T patent/LT2760860T/lt unknown
- 2012-09-27 PL PL12836986T patent/PL2760860T3/pl unknown
- 2012-09-27 SI SI201230831A patent/SI2760860T1/sl unknown
- 2012-09-27 RS RS20170167A patent/RS55680B1/sr unknown
- 2012-09-27 PT PT128369865T patent/PT2760860T/pt unknown
- 2012-09-27 TW TW101135740A patent/TW201326162A/zh unknown
- 2012-09-27 EP EP12836986.5A patent/EP2760860B8/en active Active
- 2012-09-27 JP JP2014533702A patent/JP6008972B2/ja active Active
- 2012-09-27 US US14/347,397 patent/US8962855B2/en active Active
- 2012-09-27 WO PCT/US2012/057445 patent/WO2013049279A2/en active Application Filing
- 2012-09-27 MX MX2014003839A patent/MX342746B/es active IP Right Grant
- 2012-09-27 CA CA2850541A patent/CA2850541C/en active Active
- 2012-09-27 HU HUE12836986A patent/HUE031445T2/en unknown
-
2014
- 2014-02-26 IL IL231170A patent/IL231170A/en active IP Right Grant
-
2017
- 2017-02-07 HR HRP20170196TT patent/HRP20170196T1/hr unknown
- 2017-02-10 CY CY20171100187T patent/CY1118626T1/el unknown
- 2017-02-16 SM SM201700108T patent/SMT201700108B/it unknown
Also Published As
Publication number | Publication date |
---|---|
MX2014003839A (es) | 2015-01-16 |
EP2760860B1 (en) | 2016-11-16 |
EP2760860A2 (en) | 2014-08-06 |
CA2850541C (en) | 2019-11-05 |
US20140303218A1 (en) | 2014-10-09 |
IL231170A (en) | 2015-07-30 |
AR088075A1 (es) | 2014-05-07 |
JP2014528003A (ja) | 2014-10-23 |
HUE031445T2 (en) | 2017-07-28 |
PT2760860T (pt) | 2017-02-21 |
IL231170A0 (en) | 2014-04-30 |
AU2012316084A1 (en) | 2014-03-20 |
SMT201700108B (it) | 2017-03-08 |
MX342746B (es) | 2016-10-11 |
ES2616242T3 (es) | 2017-06-12 |
CY1118626T1 (el) | 2017-07-12 |
RS55680B1 (sr) | 2017-07-31 |
EP2760860A4 (en) | 2015-04-22 |
LT2760860T (lt) | 2017-03-10 |
US8962855B2 (en) | 2015-02-24 |
SI2760860T1 (sl) | 2017-04-26 |
HRP20170196T1 (hr) | 2017-04-07 |
AU2012316084B2 (en) | 2016-10-27 |
WO2013049279A3 (en) | 2013-07-18 |
CA2850541A1 (en) | 2013-04-04 |
PL2760860T3 (pl) | 2017-06-30 |
WO2013049279A2 (en) | 2013-04-04 |
TW201326162A (zh) | 2013-07-01 |
JP6008972B2 (ja) | 2016-10-19 |
EP2760860B8 (en) | 2017-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2760860T3 (da) | Nitrogensennep-derivater | |
JP7514005B2 (ja) | がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのrasスーパーファミリーと相互作用する化合物 | |
CN112204009B (zh) | 整合应激通路的调节剂 | |
EP3452456B1 (en) | Bicyclic modulators of the integrated stress pathway | |
JP7003114B2 (ja) | 統合ストレス経路のモジュレーター | |
EP3365334B1 (en) | Benzolactam compounds as protein kinase inhibitors | |
KR20220016468A (ko) | 통합 스트레스 경로의 조절인자로서의 치환된 사이클로알킬 | |
TW201808914A (zh) | 整合應激途徑之調節劑 | |
CA3080971A1 (en) | Modulators of the integrated stress pathway | |
ES2702477T3 (es) | Compuestos (hetero) aromáticos bicíclicos fusionados útiles para el tratamiento de cánceres | |
EP3625222B1 (en) | Phenyl derivatives as pge2 receptor modulators | |
BRPI0607915A2 (pt) | composto e isÈmeros, sais, solvatos, formas quimicamente protegidas, e pró-drogas do mesmo, composição farmacêutica, e, uso de um composto ou sais farmaceuticamente aceitáveis do mesmo | |
TWI510485B (zh) | 經取代稠合咪唑衍生物及其醫藥組合物與使用方法 | |
KR20220016225A (ko) | Atr 키나제 억제제로서의 2,4,6-삼치환된 피리미딘 화합물 | |
ES2616342T3 (es) | Análogos de quinazolina y uso de análogos de quinazolina para tratar o prevenir ciertas infecciones víricas | |
US20230391769A1 (en) | Substituted heterocyclic compounds and therapeutic uses thereof | |
CN113939525A (zh) | 吉西他滨的口服活性前药 | |
WO2023147015A1 (en) | Substituted heterocyclic csnk1 inhibitors |